Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial
Retrieved on:
Tuesday, October 4, 2022
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Hypertension, Cancer, U.S. Securities and Exchange Commission, HRR, Review, Clinical trial, Man, COVID-19, Warfarin, Enzyme, Hypercalcaemia, DNA, CYP2C19, Global Oncology, Orchiectomy, Research, PSA, Arm, PFE, Global health, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Plasma, Patient, Prostate cancer, TSE, BRCA, Adult, INR, Food, CYP3A4, FDA, Breast, RPF, Testosterone, Hyponatremia, Hypermagnesemia, Risk, CYP2C8, ADT, Hyperglycemia, PARP, Melanoma, Documentation, Blood, 2, Inc., Death, Medicine, DNA repair, Metastasis, ADP, CRPC, Safety, NYSE, Breast cancer, Medivation, HER2, CYP2C9, Medical imaging, Pharmaceutical industry, Generic drug, Astellas Pharma, MCRPC, Pfizer
At the time of topline analysis, the safety of TALZENNA plus XTANDI were generally consistent with the known safety profile of each medicine.
Key Points:
- At the time of topline analysis, the safety of TALZENNA plus XTANDI were generally consistent with the known safety profile of each medicine.
- Detailed results from TALAPRO-2 will be submitted for presentation at a near-term medical congress.
- In addition to the TALAPRO-2 trial, the combination of TALZENNA plus XTANDI is being investigated in the TALAPRO-3 trial ( NCT04821622 ), a global, randomized, double-blind, placebo-controlled Phase 3 study in men with HRR-deficient mCSPC.
- Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.